MyFinsight
Home
Blog
About
Short-term marketable
securities
$171,648K
Cash and cash
equivalents
$54,063K
Prepaid expense and
other current assets
$16,006K
Receivables from related
parties
$661K
Total current assets
$242,378K
Long-term marketable
securities
$118,419K
Other non-current
assets
$12,795K
Operating lease
right-of-use asset
$2,104K
Property and equipment,
net
$878K
Restricted cash
$132K
Total assets
$376,706K
Total liabilities,
redeemable convertible...
$376,706K
Total stockholders'
equity
$323,112K
Total liabilities
$53,594K
Accumulated deficit
-$455,127K
Accumulated other
comprehensive income (loss)
-$959K
Additional paid-in capital
$779,190K
Total current
liabilities
$51,634K
Operating lease
liability, noncurrent
$1,960K
Common stock, 0.0001
par value...
$8K
Accrued research and
development liabilities
$36,841K
Accounts payable
$6,728K
Accrued compensation
and benefits
$4,387K
Accrued professional
services
$1,943K
Payables to related
parties
$986K
Operating lease
liability, current
$554K
Other accrued
liabilities
$195K
Back
Back
Balance Sheet
BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (BBOT)
source: myfinsight.com